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Figure 2b. Cumulative incidence of c-GVHD after reduced toxicity conditioning with ATG-BU-FLU and allogeneic sibling HSCT for patients with sickle cell disease (n:8).
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tolerated prednisone-hydroxyurea; only one episode of short
(3days) neurtopenic fever occured before protocol evolution;
no case of VOC or ACS or stroke or worsening of AVN (cu-
mulative 109 weeks-patients).
Therewasno (0%) transplant relatedmortality (TRM)andall
are alive (OS 100%) and free of VOC and transfusion (TFS 100%).
Engraftment: ANC recovery occurred in all (100%) at amedian
of 19 days (range 0-26 d), Platelet recovery to 20,000/ul in 100%
at amedianof 16d (10-36) and to 50,000 in 100%at amedianof
16d (11-50 d); 8 patients (89%) reached 50,000 in 21d. Hb
electrophoresis changed to donor type. Chimerism: All patient
(100%) had full (100%) myeloid chimerism. Lymphoid chi-
merism was high (>50% donor) in 6 (67%), intermediate in 1
(11%) and ﬂuctuated between 15-31% in 2 (22%).
GVHD: One (11.1%) patient developed grade II a-GVHD,
responded to steroids and only one (12.5%) of the 8 evaluable
patients developed cGVHD that responded to steroids. Peri-
transplant morbidities: Mucositis occurred in 4 (44%; grade
I in 22%, grade II in 11% and Grade III in 11%); one (11%) pa-
tient bled due to gastritis, delayed serum sickness in 1 (11%).
4 (44%) had culture-neg neutropenic fever without sepsis
and 1 (11.1%) developed line related infection. No reported
invasive fungal disease or hemorrhagic cystitis.
Conclusions: Conditioning for allo-sib-HSCT for adults with
SCA could safely and effectively be divided into: 1) Pre-
conditioning phase with steroids and Hydroxyurea to help
reduce the chronic inﬂammatory status and 2)Reduced
Toxicity Conditioning with ATG-Bu-FLU which allowed
engraftment of all patients with no peri-transplant mortality
and low rate of acute and chronic GVHD.
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Multivariate analysis of BM donors for grade 2-4 pain by race/sex: Odds Ratio (p-v
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Previous studies have identiﬁed risks of collection-related
pain and symptoms associated with sex, BMI, and age in
unrelated donors undergoing collection at NMDP centers.
We hypothesized that other important factors (race, socio-
economic status [SES], and collection center experience as
reﬂected by numbers of procedures performed) might affect
rates of pain/symptoms in donors. We assessed outcomes by
5 race categories (see Table 1), 4 SES levels, and collection
center volume. The study cohort included 2726 BM and 6768
PBSC donors collected between 2004 and 2009. Skeletal pain
and 10 symptoms were measured and scaled 1-4 as pub-
lished previously (Pulsipher, Blood 2013 121:197). Pain/
symptoms are reported as peak levels over mobilization and
collection (PBSC) or within 2 days of collection (BM) and at 1
week after collection. Generalized linear mixed models were
used to ﬁt logistic regression models with random effects by
center; the 3 main effects of race, SES, and center volume
were forced into themodel, while other donor characteristics
were added in a stepwise manner.
For PBSC donors, race was not associated with differences in
pain/symptoms during collection or 1-week post donation.
PBSC donors in higher SES levels reported higher peakalue).
Black White Other/ Unknown
1.91 (0.01) 1.0 0.63 (0.09)
0.57 (0.03) 1.0 1.29 (0.30)
Table 2
MV analysis of RDs vs. URDs pain/MTC. URDs OR ¼ 1.0
OR RDs
BM
p-value OR RDs
PBSC
p-value
Donation pain 2-4 1.20 0.352 1.63 <0.001
Donation pain 3-4 11.00 <0.001
Donation MTC 2-4 1.32 0.230 2.38 <0.001
Recovery to baseline
pain 2-4
1.18 0.535 0.79 0.031
Recovery to baseline
MTC 2-4
1.15 0.672 0.68 0.001
Table 2
Multivariate analysis of BM donors by collection center experience: Odds
Ratio (p-value).
BM
Collection
frequency
Grade 2-4
pain,
collection
Grade 2-4
symptoms,
collection
Grade 2-4
pain, 1-wk
post-
collection
Grade 2-4
symptoms,
1-wk post-
collection
>1 every 2m 1.0 1.0 1.0 1.0
1 every 2m 1.25 (<0.01) 1.41 (0.16) 1.55 (0.07) 2.09 (<0.01)
Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53 S41symptom levels 1-week post donation (p¼0.02). No pattern
of increased pain/symptoms was associated with centers
that performed smaller number of PBSC collections. For BM
donors, Black males reported signiﬁcantly higher levels of
pain after the procedure (Table 1). No differences were noted
by SES groups after BM collection. Different levels of BM
collection experience were tested to determine cutpoints;
the optimal cutpoint was noted to be 1 or fewer collections
every 2 months. BM donors from centers collecting less than
this frequency weremore likely to have persistent symptoms
(Table 2).
Conclusions: In general, race and SES have a minimal effect
on symptoms associated with donation. Of note, however,
centers performing 1 BM collection every 2 months have
more symptoms reported after BM collection, and ap-
proaches should be developed by low volume centers to
address this issue.
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Baseline and 1 year post-donation pain/MTC, and rates of recovery to
baseline levels
BM PBSC
URDs RDs p-
value
URDs RDs p-
value
Baseline skeletal
pain grade 2-4
0.46% 2.42% 0.039 0.61% 8.38% <0.001
Baseline skeletal
pain grade 3-4
0% 0% 1.000 0% 1.85% <0.001
Baseline max MTC 2-4 0.82% 0.81% 1.000 0.51% 2.57% <0.001
1yr skeletal pain 2-4 5.00% 10.64% 0.033 5.37% 14.27% <0.001
1yr MTC 2-4 4.61% 7.45% 0.211 3.79% 6.04% 0.012
% back to baseline
pain at 1 yr
77.11% 78.72% 0.795 78.32% 68.51% <0.001
% back to baseline
MTC at 1 yr
84.61% 87.10% 0.646 88.22% 83.31% <0.001Program, Minneapolis, MN; 6University of Pittsburgh,
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Texas MD Anderson Cancer Center, Houston, TX; 9 Department
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Prospective data regarding donation related toxicities in
related donors (RDs) of bone marrow (BM) and peripheral
blood stem cells (PBSC) are limited. To address this, the
NHLBI-funded Related Donor Safety Study (RDSafe;
NCT00948636) prospectively enrolled adult RDs between
2010 and 2013 at 54 transplant centers in the United States.
RDswere assessed for baseline health status and followed for
1 year after donation, collecting detailed information on
adverse events, pain levels and 10 donation-relatedmodiﬁed
NCI-CTC symptoms (MTC). A concurrently enrolled cohort of
NMDP unrelated donors (URDs) was assessed as a compar-
ator. This report compares baseline, donation, and 1 year
post-donation pain/MTC for RDs aged 18-60: 124 BM (38
centers, med age 33, 48% female) and 919 PBSC (42 centers,
med age 49, 44% female) to URDs: 1098 BM (18 centers, med
age 31, 42% female) and 3119 PBSC (20 centers, med age 31,
40% female).
Results: RDs of PBSC had higher levels of baseline grade 2-4
pain and MTC compared to URDs; RDs of BM had higher
baseline levels of pain, but not MTC (Table 1). Multivariable
analysis (Table 2) showed similar donation-related pain
and MTC rates of recovery for RDs and URDs of BM. In
contrast, RDs of PBSC had signiﬁcant increases in risk ofFigure 1. Skeletal Pain experienced by PBSC donor, by unrelated vs related, at
baseline, donation, and 1 year post-donation. (Skeletal pain represents pain in
at least one of the following sites: back, bone, headache, hip, limb, joint, and
neck.) The severity of skeletal pain is deﬁned as the maximum grade among
these pain sites.
